{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T12:07:22Z","timestamp":1775736442381,"version":"3.50.1"},"reference-count":18,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2009,5,4]],"date-time":"2009-05-04T00:00:00Z","timestamp":1241395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2009,7]]},"abstract":"<jats:sec><jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> A new 8%\u00a0ciclopirox\u2010medicated nail lacquer (P\u20103051), based on a new technology, revealed superior properties in terms of affinity to keratin, nail permeation, and ease of use.<\/jats:p><jats:p><jats:bold>Objective\u2002<\/jats:bold> This study aims to assess the efficacy and safety of P\u20103051 vs. the market 8% ciclopirox nail lacquer.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> This is a multicentre, randomized, three\u2010arm, placebo\u2010controlled, parallel groups, evaluator\u2010blinded study. Overall, 467 patients with onychomycosis of at least one big toenail were randomized to receive P\u20103051, the reference drug or placebo in a 2\u00a0:\u00a02\u00a0:\u00a01 ratio for a 48\u2010week treatment by daily application, followed by a 12\u2010week follow\u2010up.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> The study satisfied its objective by demonstrating that P\u20103051 was both superior to placebo and non\u2010inferior to reference in the complete cure rate after a 48\u2010week active treatment period. Switching the non\u2010inferiority to superiority hypothesis, the superiority of P\u20103051 vs. reference was nearly significant at week\u00a048 (confirmed at week\u00a052), and it was significant at week\u00a060 (cure rate for P\u20103051\u00a0is 119% higher than reference; <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.05). Altogether, the results on primary endpoint exceed expectations; superiority test was performed also on secondary endpoints to confirm the superiority trend of the study. At the end of follow\u2010up, percentages of patients who achieved the endpoint \u2018responder\u2019 in the P\u20103051 group were 66% higher than reference (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.05), and those who achieved the endpoint \u2018decrease of diseased nail\u2019 were 40% higher (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.05).<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> Ciclopirox 8% hydrolacquer is more active than reference ciclopirox nail lacquer in the treatment of onychomycosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conflicts of interest<\/jats:title><jats:p>None declared.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-3083.2009.03164.x","type":"journal-article","created":{"date-parts":[[2009,5,5]],"date-time":"2009-05-05T03:45:09Z","timestamp":1241495109000},"page":"773-781","source":"Crossref","is-referenced-by-count":81,"title":["An innovative water\u2010soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis"],"prefix":"10.1111","volume":"23","author":[{"given":"R","family":"Baran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Tosti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Hartmane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Altmeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Hercogova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Koudelkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Ruzicka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Combemale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Mikazans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,6,3]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1081\/DDC-43935"},{"key":"e_1_2_6_3_2","unstructured":"MaillandF Dal BoL.In vitroantifungal activity and model of nail permeation of ciclopirox in a hidroxypropyl\u2010chitosan nail lacquer. Proceedings of the 21st World Congress of Dermatology 30\u00a0September\u20135\u00a0October 2007 Buenos\u00a0Aires Argentina."},{"key":"e_1_2_6_4_2","unstructured":"BaranR MaillandF.Transungual delivery of drugs: new perspectives (Abstract No. 435). Proceedings of the 34th Annual European Society for Dermatological Research (ESDR) Meeting 9\u201311 September 2004 Vienna Austria."},{"key":"e_1_2_6_5_2","unstructured":"LegoraM MaillandF.Mechanism of adherence to the nail surface of a film formed by water soluble chitosan. Proceedings of the 16th Congress of the European Academy of Dermatology and Venereology 16\u201320 May 2007 Vienna Austria."},{"key":"e_1_2_6_6_2","unstructured":"MaillandF Dal BoL FrisendaL.Ciclopirox nail concentrationsin vitroand after single and multiple applications on healthy fingernails of a hydroxypropyl\u2010chitosan based nail lacquer. Proceedings of the 21st World Congress of Dermatology 30\u00a0September\u20135\u00a0October 2007 Buenos\u00a0Aires Argentina."},{"key":"e_1_2_6_7_2","first-page":"488","article-title":"Computerized image analysis of nails affected by fungal infection: evaluation using digital photographs and manually defined areas","volume":"3","author":"Baran R","year":"2004","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.3109\/15569528209051516"},{"key":"e_1_2_6_9_2","volume-title":"Guidance for Industry: Skin Irritation and Sensitization Testing of Generic Transdermal Drug Products","author":"Center for Drug Evaluation and Research, US Food and Drug Administration","year":"1999"},{"key":"e_1_2_6_10_2","volume-title":"Points to Consider on Switching Between Superiority and Non\u2010inferiority","author":"European Agency for the Evaluation of Medicinal Products","year":"1999"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.109071"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1201\/b14710"},{"key":"e_1_2_6_13_2","unstructured":"Terbinafine: Official FDA Information \u2013 Side Effects and Uses. [WWW document]\u00a0http:\/\/www.drugs.com\/pro\/terbinafine.html(last accessed 5\u00a0December\u00a02008)."},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10227-002-0139-9"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546630252775171"},{"key":"e_1_2_6_16_2","unstructured":"Fluconazole: Official FDA Information \u2013 Side Effects and Uses. [WWW document]\u00a0http:\/\/www.drugs.com\/pro\/fluconazole.html(last accessed 5 December 2008)."},{"key":"e_1_2_6_17_2","unstructured":"Sporanox: Official FDA Information \u2013 Side Effects and Uses. [WWW document]\u00a0http:\/\/www.drugs.com\/pro\/sporanox.html(last accessed 5 December 2008)."},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1992.tb00278.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.12.019"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2009.03164.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2009.03164.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T07:34:23Z","timestamp":1697355263000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2009.03164.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,3]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["10.1111\/j.1468-3083.2009.03164.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2009.03164.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,3]]}}}